Published in Circulation on January 29, 2007
Multiple Electrode Aggregometry & Clopidogrel Resistance | NCT01991093
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2010) 1.34
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care (2009) 1.03
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med (2011) 0.93
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol (2010) 0.88
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Endovascular treatment of extracranial vertebral artery stenosis. World J Radiol (2012) 0.87
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J (2008) 0.85
Antiplatelet drugs in cardiological practice: established strategies and new developments. Vasc Health Risk Manag (2008) 0.84
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr (2010) 0.84
Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81
Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. Int J Cardiovasc Imaging (2007) 0.81
Can doubling the maintenance dose of clopidogrel prevent from early stent thrombosis after the primary percutaneous coronary intervention? ARYA Atheroscler (2011) 0.80
The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol (2009) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs. Int J Vasc Med (2011) 0.78
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med (2011) 0.78
Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation. Korean Circ J (2009) 0.78
Antiplatelet Resistance-Does it Exist and How to Measure it? Clin Med Cardiol (2009) 0.78
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag (2009) 0.77
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep (2015) 0.77
TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther (2011) 0.77
Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. Thromb J (2007) 0.76
Evidenced-based antithrombotic therapy for acute coronary syndromes. Diabetes (2013) 0.75
State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. Curr Cardiovasc Risk Rep (2015) 0.75
Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study. J Clin Diagn Res (2013) 0.75
Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart (2016) 0.75
The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses. Thrombosis (2009) 0.75
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. Vasc Health Risk Manag (2011) 0.75
Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy. Yonsei Med J (2013) 0.75
Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel. Am J Cardiovasc Dis (2017) 0.75
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2016) 0.75
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vasc Health Risk Manag (2009) 0.75
Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. Am J Cardiovasc Dis (2011) 0.75
ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel. Meta Gene (2014) 0.75
Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. Eur J Clin Pharmacol (2007) 0.75
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. J Am Heart Assoc (2017) 0.75
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol (2011) 0.75
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol (2011) 4.59
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol (2007) 2.73
Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv (2009) 2.64
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv (2011) 2.34
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol (2007) 1.94
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol (2006) 1.94
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes (2005) 1.88
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol (2006) 1.84
Spontaneous coronary artery dissection: long-term follow-up of a large series of patients prospectively managed with a "conservative" therapeutic strategy. JACC Cardiovasc Interv (2012) 1.81
Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol (2008) 1.78
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J (2008) 1.77
High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J (2004) 1.77
Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol (2004) 1.75
Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol (2006) 1.71
Candidates for transcatheter aortic valve replacement: fitting the PARTNERS criteria. Catheter Cardiovasc Interv (2013) 1.61
Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv (2008) 1.61
Intravascular optical coherence tomography detection of atherosclerosis and inflammation in murine aorta. Arterioscler Thromb Vasc Biol (2012) 1.61
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance? Catheter Cardiovasc Interv (2004) 1.52
Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A (2003) 1.51
Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes (2006) 1.49
Feasibility and safety of the second-generation, frequency domain optical coherence tomography (FD-OCT): a multicenter study. J Invasive Cardiol (2012) 1.47
Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J (2004) 1.47
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci U S A (2012) 1.46
LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. Eur Heart J (2005) 1.45
The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv (2012) 1.44
Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol (2010) 1.44
Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol (2004) 1.43
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv (2012) 1.43
Three-dimensional imaging of fibrous cap by frequency-domain optical coherence tomography. Catheter Cardiovasc Interv (2012) 1.43
Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. J Am Coll Cardiol (2007) 1.43
Heterogeneity of atherosclerotic plaque characteristics in human coronary artery disease: a three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv (2007) 1.42
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Diagnostic accuracy of intravascular ultrasound-derived minimal lumen area compared with fractional flow reserve--meta-analysis: pooled accuracy of IVUS luminal area versus FFR. Catheter Cardiovasc Interv (2014) 1.42
Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.L.R.trial. Catheter Cardiovasc Interv (2009) 1.41
Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study ("Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo"). J Thromb Thrombolysis (2013) 1.40
Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. Catheter Cardiovasc Interv (2009) 1.39
Retracted Reanalysis of the gene expression profile in chronic pancreatitis via bioinformatics methods. Eur J Med Res (2014) 1.39
Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv (2010) 1.38
Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J (2010) 1.37
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes (2006) 1.27
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol (2010) 1.26
Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res (2005) 1.25
The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem (2005) 1.22
Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs. J Virol (2006) 1.20
Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res (2005) 1.18
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res (2005) 1.17
Volumetric quantification of fibrous caps using intravascular optical coherence tomography. Biomed Opt Express (2012) 1.15
Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2003) 1.11
Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation (2003) 1.11
Crystal structure of albaflavenone monooxygenase containing a moonlighting terpene synthase active site. J Biol Chem (2009) 1.10
Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol (2011) 1.09
The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein. PLoS Pathog (2010) 1.08
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol (2008) 1.08
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res (2005) 1.07
New frontiers in cardiology: drug-eluting stents: Part I. Circulation (2003) 1.06
The canine papillomavirus e5 protein signals from the endoplasmic reticulum. J Virol (2009) 1.05
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol (2010) 1.05
Optical coherence tomography versus intravascular ultrasound to evaluate coronary artery disease and percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.02
Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation (2005) 1.01
Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med (2012) 1.01
In vitro validation of new Fourier-domain optical coherence tomography. EuroIntervention (2011) 1.00
TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal (2013) 0.97
Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy. Transl Res (2010) 0.97
FOG2 protein down-regulation by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. J Biol Chem (2013) 0.97